Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | GFER | P55789 | 1/20 | 0.32 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.31 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2164878 | 0.89 | DRD1 (0.34) | MAPTSLC6A4PPARGPPARAALOX15 | |
| SCHEMBL4323295 | 0.80 | LDHA (0.45) | LDHAMAPTKDM4EPOLBCYP2A6 | |
| SCHEMBL10582426 | 0.80 | ALDH1A1 (0.38) | MAPTSLC6A4PPARGPPARALMNA | |
| SCHEMBL9143036 | 0.78 | ESR2 (0.46) | MEN1KMT2A | |
| SCHEMBL9642543 | 0.78 | TDP1 (0.42) | MAPTKDM4EPOLBGFERTDP1 | |
| SCHEMBL10028300 | 0.78 | ACHE (0.41) | MAPTPOLBCA1CA2CA9 | |
| SCHEMBL29270714 | 0.78 | TRPA1 (0.33) | POLBPPARGPPARAALDH1A1TSHR | |
| SCHEMBL2164230 | 0.77 | KDM4E (0.40) | MAPTKDM4EPOLBSLC6A4PPARG | |
| SCHEMBL2833080 | 0.77 | LDHA (0.42) | LDHAMAPTKDM4ECYP2A6CA1 | |
| SCHEMBL943897 | 0.77 | PTPRZ1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7485644-B2 | N-{'4-substituted piperazine-1-sulfonylmethylalkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2009-02-03 | — | — | US | disclosed |
| EP-1644340-B1 | N-[({'4-SUBSTITUTED PIPERAZINE-1-YL}SULFONYLMETHYL)ALKYL]-N-HYDROXYFORMAMIDE COMPOUNDS AS METALLOPROTEINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-11-12 | — | — | EP | disclosed |
| US-20070197542-A1 | N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2007-08-23 | — | — | US | disclosed |
| US-7119203-B2 | Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION (US) | 2006-10-10 | — | — | US | disclosed |
| US-20050209278-A1 | Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION | 2005-09-22 | — | — | US | disclosed |
| EP-1565459-A2 | HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS | Pharmacia Corporation (US) | 2005-08-24 | — | — | EP | disclosed |
| EP-1501827-A2 | PIPERIDINYL-AND PIPERAZINYL-SULFONYLMETHYL HYDROXAMIC ACID AND THEIR USE AS PROTEASE INHIBITORS | Pharmacia Corporation (US) | 2005-02-02 | — | — | EP | disclosed |
| US-20050009838-A1 | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | PHARMACIA CORPORATION | 2005-01-13 | — | — | US | disclosed |
| US-20040142979-A1 | Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors | PHARMACIA CORPORATION | 2004-07-22 | — | — | US | disclosed |
| WO-2004048368-A2 | HETEROARYLSULFONYLMETHYL HYDROXAMIC ACIDS AND AMIDES AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
| WO-2003091247-A2 | PIPERIDINYL-AND PIPERAZINYL-SULFONYLMETHYL HYDROXAMIC ACIDS AND THEIR USE AS PROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-11-06 | — | — | WO | disclosed |
| EP-1095071-A1 | AROMATIC POLYMERS WITH PENDANT FLUORINATED IONIC GROUPS | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2001-05-02 | — | — | EP | disclosed |
| WO-1999067304-A1 | AROMATIC POLYMERS WITH PENDANT FLUORINATED IONIC GROUPS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-12-29 | — | — | WO | disclosed |
| US-5730904-A | Partially fluroinated benzene derivatives, and liquid-crystalline medium | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1998-03-24 | — | — | US | disclosed |
| WO-1994026840-A1 | PARTIALLY FLUORINATED BENZENE DERIVATIVES AND THEIR USE IN LIQUID-CRYSTAL MEDIA | MERCK PATENT GMBH (DE) | 1994-11-24 | — | — | WO | disclosed |
| US-5348677-A | Electro-optical liquid crystal display element | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1994-09-20 | — | — | US | disclosed |
| US-5196140-A | ELECTRO-OPTICAL LIQUID CRYSTAL DISPLAY ELEMENT | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-03-23 | — | — | US | disclosed |
| EP-0313604-B1 | ELECTRO-OPTICAL LIQUID CRYSTAL DISPLAY ELEMENT | MERCK PATENT GmbH (DE) | 1992-03-25 | — | — | EP | disclosed |
| EP-0313604-A1 | ELECTRO-OPTICAL LIQUID CRYSTAL DISPLAY ELEMENT. | MERCK PATENT GMBH (DE) | 1989-05-03 | — | — | EP | disclosed |
| WO-1988008441-A1 | ELECTRO-OPTICAL LIQUID CRYSTAL DISPLAY ELEMENT | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1988-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209278-A1 | Piperidinyl- and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | MMP1, PREP, MMP3 | LDHA 1163/4885MAPT 4135/4885KDM4E 1152/4885 |
| US-20040142979-A1 | Heteroarylsulfonylmethyl hydroxamic acids and amides and their use as protease inhibitors | MMP3, MMP13, MMP10 | LDHA 794/4885MAPT 3438/4885KDM4E 1844/4885 |
| US-20050009838-A1 | Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors | MMP1, PREP, MMP3 | LDHA 1163/4885MAPT 4135/4885KDM4E 1152/4885 |
| US-20070197542-A1 | N-{'4-substituted piperazine-1-sulfonylmethyl!alkyl}-n-hydroxyfomamide compounds as metalloproteinase inhibitors | MMP26, MMP9, MMP3 | LDHA 4297/4885MAPT 4413/4885KDM4E 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.